ES2570127T3 - Compuestos y composiciones como inhibidores de la proteína quinasa - Google Patents

Compuestos y composiciones como inhibidores de la proteína quinasa

Info

Publication number
ES2570127T3
ES2570127T3 ES09730392T ES09730392T ES2570127T3 ES 2570127 T3 ES2570127 T3 ES 2570127T3 ES 09730392 T ES09730392 T ES 09730392T ES 09730392 T ES09730392 T ES 09730392T ES 2570127 T3 ES2570127 T3 ES 2570127T3
Authority
ES
Spain
Prior art keywords
substituted
6alkyl
alkyl
halogen
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09730392T
Other languages
English (en)
Inventor
Bei Chen
Tao Jiang
Thomas H Marsilje
Pierre-Yves Michellys
Truc Ngoc Nguyen
Wei Pei
Baogen Wu
Zhaobo Gao
Yonghui Ge
Chen Huang
Yuncheng Li
Xuefeng Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2570127T3 publication Critical patent/ES2570127T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de fórmula (1)**Fórmula** o una sal fisiológicamente aceptable del mismo; R1 and R2 are independently H, C1-6 alkyl or halo-substituted C1-6 alkyl; R1 y R2 son independientemente H, alquilo de C1-6 o halógeno alquilo sustituido de C1-6 R3 es halo, alquilo de C1-6, o alquilo de C1-6 sustituido por halo; R4 es H; Alternativamente, R3 y R4 junto con los átomos de carbono a los que están unidos a pueden formar un anillo de 5-6 miembros que contiene 1-3 heteroátomos seleccionados entre N, O y S y opcionalmente sustituidos con 1-2 grupos R10 en el que R10 es halógeno, fenilo alquilo C1-6, alquenilo C2-6, alquinilo C2-6, opcionalmente sustituido o NR2; R5 y R6 son independientemente alquilo C1-6, alcoxi C1-6, alquenilo C2-6 o alquinilo C2-6, cada uno de los cuales puede estar opcionalmente sustituido con grupos halógeno, amino o hidroxilo; halógeno, nitro, ciano, CR (OR17) R17, OR17, NR (R17), CR (R17) NRR17 (CR2)qY, C(O)O0-1R17, C(O)NR(R17), C(O)CRR17-NR(R17), C(O)NR(CR2)pNR(R17), C(O)NR(CR2)pOR17, C(O)NR(CR2) pSR17, C(O)NR(CR2)pS(O)1-2R18, S(O)0-2R18, (CR2)1-6NR(CR2)pOR17, (CR2)1-6NR(CR2)qC(O)R18, S(O)2NRR17, S(O)2NR (CR2) pNR (R17), o S(O)2NR(CR2)pOR17; R7 es S(O)0-2R19, S(O)2NRR20 o C(O)NR(R20); en el que R19 y R20 son independientemente alquilo C1-6, halógeno sustituido C1-6 alquilo o cicloalquilo C3-7; o R20 es H; cada R9 es independientemente -L-CR(OR17)-CtF (2t + 1) donde t es 1-3; -L-C(O)-CR (R17) -NRR17, -L-C(O)-NR- (CR2)p-NRR17, -LC(O)NR(CR2)pOR17, -LC(O)-(CR2)q-NR-C(O)-R18, -LC(O)NR(CR2)pSR17, -LC(O)NR(CR2)pS(O)1-2R18, (CR2)pNR(CR2)pOR17 o (CR2)pNR-LC(O)R18, -LS(O)2R18, -LS(O)2NRR17, -LS(O)2NR(CR2)pNR(R17), -L-S(O)2NR (CR2)pOR17 o un radical seleccionado de la fórmula (a), (b), (c) o (d):**Fórmula** en el que R11, R12, R13, R14, R15 y R16 se seleccionan independientemente de H, o alquilo C1-6, alcoxi C1-6, alquenilo C2-6 o alquinilo C2-6, cada uno de los cuales puede estar opcionalmente sustituido con grupos halógenogen, amino o idroxilo; o R11 y R12, R12 y R15, R15 y R16, R13 y R14, o R13 y R15 junto con los átomos de carbono y / o nitrógeno a los que están unidos pueden formar un anillo saturado, insaturado o parcialmente insaturado de 3-7 miembros que contiene opcionalmente hasta 3 átomos o grupos seleccionados de entre C(O), N, O y S(O)0-2; L es (CR2)1-4 o un enlace; R17 y R18 son independientemente alquilo C1-6, alquilo C1-6 halógeno sustituido, alquenilo C2-6 o alquinilo C2-6; o R17 es H; Y es un anillo carbocíclico C3-12, arilo C6-10; o un heteroarilo de 5-10 miembros o 4-10 miembros de anillo heterocíclico; cada uno de los cuales está opcionalmente sustituido con 1-3 grupos R6; cada R es H o alquilo C1-6; p es 2-4; y q es 0-4.
ES09730392T 2008-04-07 2009-04-03 Compuestos y composiciones como inhibidores de la proteína quinasa Active ES2570127T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4311108P 2008-04-07 2008-04-07
US11602308P 2008-11-19 2008-11-19
PCT/US2009/039383 WO2009126515A1 (en) 2008-04-07 2009-04-03 Compounds and compositions as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
ES2570127T3 true ES2570127T3 (es) 2016-05-17

Family

ID=40756678

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09730392T Active ES2570127T3 (es) 2008-04-07 2009-04-03 Compuestos y composiciones como inhibidores de la proteína quinasa

Country Status (12)

Country Link
US (1) US8592432B2 (es)
EP (1) EP2271630B1 (es)
JP (1) JP5298187B2 (es)
KR (1) KR101238585B1 (es)
CN (1) CN102131788B (es)
AU (1) AU2009233964B2 (es)
BR (1) BRPI0911228A2 (es)
CA (1) CA2720946C (es)
EA (1) EA018282B1 (es)
ES (1) ES2570127T3 (es)
MX (1) MX2010010968A (es)
WO (1) WO2009126515A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
MX2010012703A (es) 2008-05-21 2010-12-21 Ariad Pharma Inc Derivados fosforosos como inhibidores de cinasa.
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
PT2394999E (pt) * 2009-02-06 2014-05-02 Nippon Shinyaku Co Ltd Derivado de aminopirazina e medicamento correspondente
CA2760061C (en) 2009-05-08 2017-02-28 Astellas Pharma Inc. Diamino heterocyclic carboxamide compound
MX342164B (es) * 2010-06-23 2016-09-19 Hanmi Science Co Ltd Derivados de pirimidina fusionados novedosos para la inhibicion de la actividad de tirosina cinasa.
JPWO2012005299A1 (ja) * 2010-07-07 2013-09-05 日本新薬株式会社 Ｒｏｓチロシンキナーゼ阻害剤
BR112013008240A2 (pt) * 2010-10-08 2017-12-12 Abbvie Inc compostos de furo [3-2-d] pirimidina
MX2013004086A (es) * 2010-10-14 2013-07-05 Ariad Pharma Inc Metodos para inhibir proliferacion celular en cancers accionados por egfr.
BR112013015000A2 (pt) * 2010-12-17 2016-08-09 Novartis Ag formas cristalinas de 5-cloron2-(2-isopropóxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propano-2-sulfonil)-fenil]-pirimidina-2,4-diamina
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
BR112013019643B1 (pt) * 2011-02-02 2022-04-19 Novartis Ag Uso de inibidores de álcali
CN102757390B (zh) * 2011-04-27 2015-04-22 中国中化股份有限公司 一种制备2-甲氧基-4-肼基-5-氟嘧啶的方法
BR112013027734A2 (pt) 2011-05-04 2017-08-08 Ariad Pharma Inc compostos para a inibição de proliferação celular em cânceres impulsionados pelo egfr, método e composição farmacêutica
KR101379808B1 (ko) 2012-04-03 2014-04-24 울산대학교 산학협력단 산화질소 생성 억제용 피라졸로피리미딘 유도체 화합물
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
CN104854101B (zh) * 2012-11-06 2018-05-01 上海复尚慧创医药研究有限公司 Alk激酶抑制剂
CN102977104A (zh) * 2012-11-26 2013-03-20 盛世泰科生物医药技术(苏州)有限公司 2,4-二氯-7-氢-吡咯并（2,3）嘧啶的合成
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN104109149B (zh) * 2013-04-22 2018-09-28 苏州泽璟生物制药有限公司 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物
CN104672214B (zh) * 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
RU2016129953A (ru) * 2013-12-23 2018-01-30 Новартис Аг Фармацевтические комбинации
CN106164076B (zh) 2014-03-27 2019-03-26 詹森药业有限公司 作为ros1抑制剂的化合物
WO2015194764A2 (ko) * 2014-06-17 2015-12-23 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
CN105524045B (zh) * 2014-10-22 2020-04-10 山东轩竹医药科技有限公司 四环类间变性淋巴瘤激酶抑制剂
CN104803908A (zh) 2015-03-26 2015-07-29 药源药物化学（上海）有限公司 2-异丙氧基-5-甲基-4-(4-哌啶基)苯胺二盐酸盐的水合物、其制备方法及用途
CN106188060A (zh) * 2015-04-29 2016-12-07 厦门大学 嘧啶并吡咯类化合物、其制备方法、药用组合物及其应用
CN106699810A (zh) * 2015-11-17 2017-05-24 清华大学 一种含氮杂环化合物及其制备方法与在抑制激酶活性中的应用
CN107216319B (zh) * 2016-03-21 2021-10-08 中国科学院上海药物研究所 一种2，4-二氨基嘧啶类衍生物、其制备方法及用途
KR101937529B1 (ko) * 2016-07-26 2019-01-14 한국화학연구원 신규한 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
NZ751713A (en) 2016-08-29 2022-07-01 Univ Michigan Regents Aminopyrimidines as alk inhibitors
CN107793417B (zh) * 2016-09-05 2020-06-09 复旦大学 吡咯并[2,3-d]嘧啶类化合物及其盐，及制备方法和药用用途
KR102477063B1 (ko) * 2016-10-28 2022-12-12 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 헤테로비시클릭 화합물
CN108276410B (zh) * 2017-01-06 2021-12-10 首药控股(北京)股份有限公司 一种间变性淋巴瘤激酶抑制剂及其制备方法和用途
KR102032418B1 (ko) * 2017-06-15 2019-10-16 한국화학연구원 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
US20190338244A1 (en) * 2017-11-30 2019-11-07 New York Medical College Multipotent adult stem cells: characterization and use
CN112645929B (zh) * 2019-10-11 2022-03-11 苏州泽璟生物制药股份有限公司 异丙磺酰基苯基嘧啶类化合物或其盐的多晶型物
US20230133169A1 (en) * 2019-10-17 2023-05-04 Betta Pharmaceuticals Co., Ltd Egfr inhibitor, composition, and method for preparation thereof
CN111484484B (zh) * 2020-04-13 2021-11-23 沈阳药科大学 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用
AU2022426300B2 (en) * 2021-12-30 2025-09-18 Korea Research Institute Of Chemical Technology Pyrazolopyrimidine derivative and anticancer pharmaceutical composition containing same as active ingredient
KR102847312B1 (ko) * 2021-12-30 2025-08-19 한국화학연구원 피라졸로피리미딘 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
CN114805301B (zh) * 2022-04-29 2024-04-05 沈阳药科大学 2,4-二芳氨基嘧啶类化合物及其制备方法和应用
CN116284001B (zh) * 2023-01-30 2025-06-06 中国药科大学 Dclk1抑制剂、制备方法、药物组合物和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69627195T2 (de) * 1995-11-01 2004-01-29 Novartis Ag Purinderivate und verfahren zu ihrer herstellung
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP4886511B2 (ja) * 2003-07-30 2012-02-29 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法
JP4741491B2 (ja) * 2003-08-07 2011-08-03 ライジェル ファーマシューティカルズ， インコーポレイテッド 抗増殖剤としての２，４−ピリミジンジアミン化合物および使用
BR122019017579B8 (pt) 2003-08-15 2021-07-27 Novartis Ag 2,4-pirimidinadiaminas, seus usos, combinação e composição farmacêutica
BRPI0510963A (pt) * 2004-05-14 2007-11-20 Pfizer Prod Inc derivados pirimidina para o tratamento do crescimento anormal de células
EP1598343A1 (de) * 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
BRPI0517887A (pt) * 2004-11-24 2008-10-21 Novartis Ag combinações de inibidores de jaks
JP2008013527A (ja) * 2006-07-10 2008-01-24 Sankyo Co Ltd チエノ［３，２−ｄ］ピリミジン−２，４−ジアミン誘導体
WO2008039359A2 (en) * 2006-09-25 2008-04-03 Janssen Pharmaceutica N.V. Bicyclic pyrimidine kinase inhibitors
EP2222647B1 (en) 2006-10-23 2015-08-05 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
KR101364277B1 (ko) * 2006-12-08 2014-02-21 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물
ME00811B (me) 2006-12-08 2012-03-20 Novartis Ag JEDINJENJA l KOMPOZICIJE KAO INHIBITORI PROTEIN KINAZE
WO2009032694A1 (en) 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
MX2010002336A (es) * 2007-08-28 2010-03-25 Irm Llc Derivados de 2-bifenil-amino-4-amino-pirimidina como inhibidores de cinasa.

Also Published As

Publication number Publication date
EP2271630A1 (en) 2011-01-12
AU2009233964B2 (en) 2012-06-07
EA018282B1 (ru) 2013-06-28
MX2010010968A (es) 2010-10-26
KR20110015414A (ko) 2011-02-15
WO2009126515A8 (en) 2010-10-21
AU2009233964A1 (en) 2009-10-15
KR101238585B1 (ko) 2013-02-28
CN102131788B (zh) 2014-03-19
CA2720946A1 (en) 2009-10-15
BRPI0911228A2 (pt) 2017-05-30
WO2009126515A1 (en) 2009-10-15
US20110135668A1 (en) 2011-06-09
JP2011516555A (ja) 2011-05-26
US8592432B2 (en) 2013-11-26
EA201001597A1 (ru) 2011-06-30
CN102131788A (zh) 2011-07-20
EP2271630B1 (en) 2016-03-23
CA2720946C (en) 2013-05-28
JP5298187B2 (ja) 2013-09-25

Similar Documents

Publication Publication Date Title
ES2570127T3 (es) Compuestos y composiciones como inhibidores de la proteína quinasa
PE20141827A1 (es) Inhibidores de proteinas quinasas
AR071300A1 (es) Compuestos; composiciones farmaceuticas en base al compuesto y uso del mismo para la manufactura de un medicamento
AR056536A1 (es) Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace)
CO6170361A2 (es) Composiciones y metodos para modular receptores de c-kit y pdgfr
AR059338A1 (es) N-fenilbenzotriazolilo como inhibidores de c-kit
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR067478A1 (es) Compuestos derivados de morfolina pirimidina
AR082109A1 (es) Derivados de bipiridilo
AR062510A1 (es) Derivados de piridona con actividad antagonista de mch y medicamentos que comprenden estos compuestos
AR072787A1 (es) Compuestos y composiciones como inhibidores de cinasa
AR070636A1 (es) Derivados de piridina, composicion farmaceutica y uso terapeutico
AR046767A1 (es) Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1
EA201171333A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-с-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
UY28756A1 (es) Compuestos
AR041250A1 (es) Derivados de sulfonamida como inhibidores de enzimas convertidoras de tnf-alfa
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
PE20121506A1 (es) Compuestos triazolopiridinas como inhibidores de c-met
AR067327A1 (es) Derivados de piperidina / piperazina
PE20070832A1 (es) Derivados de piridazinona como inhibidores de la tirosina quinasa
PE20070112A1 (es) Mimeticos de glucocorticoides, metodos para su fabricacion, composiciones farmaceuticas y usos de los mismos
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
AR060875A1 (es) Derivados de 2-piridona como inhibidores de la neutrofilo elastasa humana
AR085637A1 (es) Derivados de pirido[2,3-b]pirazina
AR075583A1 (es) Derivados de isoxazol/o-piridina con eslabon etilo o etenilo